Poland halts three batches of chemotherapy drug Fluorouracil Accord over quality defect

Poland's Chief Pharmaceutical Inspector has halted the distribution of the anticancer drug Fluorouracil Accord (50 mg/ml) across the country, affecting three batches of the product. The suspension is due to a confirmed quality defect in the medication. The decision carries immediate enforcement, requiring the product to be pulled from sale without delay.